UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 205

Sortiert nach

A Validation Study of Multicenter Diffusion Tensor Imaging: Reliability of Fractional Anisotropy and Diffusivity Values

American journal of neuroradiology : AJNR, 2012-04, Vol.33 (4), p.695-700

2012

Volltextzugriff (PDF)

Manual Segmentation of MS Cortical Lesions Using MRI: A Comparison of 3 MRI Reading Protocols

American journal of neuroradiology : AJNR, 2016-09, Vol.37 (9), p.1623-1628

2016

Volltextzugriff (PDF)

Diffusion tensor imaging and cognitive speed in children with multiple sclerosis

Journal of the neurological sciences, 2011-10, Vol.309 (1), p.68-74

2011

Volltextzugriff (PDF)

Daclizumab HYP reduces total disability burden of patients with multiple sclerosis: results from an exploratory area under the curve analysis

Journal of the neurological sciences, 2015-10, Vol.357, p.e300-e301

2015

Volltextzugriff (PDF)

Regional variations in normal brain shown by quantitative magnetization transfer imaging

Magnetic resonance in medicine, 2004-02, Vol.51 (2), p.299-303

2004

Volltextzugriff (PDF)

Entorhinal cortex atrophy in epilepsy patients exhibiting normal hippocampal volumes

Neurology, 2001-05, Vol.56 (10), p.1335

2001

Volltextzugriff (PDF)

Neuroradiological efficacy of oral BG-12 for relapsing–/INS;remitting multiple sclerosis (RRMS): Integrated analysis of the Phase 3 DEFINE and CONFIRM studies

Journal of the neurological sciences, 2013-10, Vol.333, p.e368-e368

2013

Volltextzugriff (PDF)

Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): Analysis from the phase 3 CARE-MS I study

Journal of the neurological sciences, 2013-10, Vol.333, p.e375-e375

2013

Volltextzugriff (PDF)

Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study)

Journal of the neurological sciences, 2013-10, Vol.333, p.e374-e375

2013

Volltextzugriff (PDF)

Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy

Journal of the neurological sciences, 2013-10, Vol.333, p.e375-e376

2013

Volltextzugriff (PDF)

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

The New England journal of medicine, 2015-10, Vol.373 (15), p.1418-1428

2015

Volltextzugriff (PDF)

PND63 Effects of BG-12 on Quality of Life in Relapsing–Remitting Multiple Sclerosis: Findings From the Phase 3 Define Study

Value in health, 2012-11, Vol.15 (7), p.A557-A557

2012

Volltextzugriff (PDF)

Comparison of Multiple Sclerosis Cortical Lesion Types Detected by Multicontrast 3T and 7T MRI

American journal of neuroradiology : AJNR, 2019-07, Vol.40 (7), p.1162-1169

2019

Volltextzugriff (PDF)

Differential Regional Brain Atrophy Following Prophylactic Cranial Irradiation in Small Cell Lung Cancer Patients

International journal of radiation oncology, biology, physics, 2008, Vol.72 (1), p.S232-S232

2008

Volltextzugriff (PDF)

Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions

American journal of neuroradiology : AJNR, 2020-09, Vol.41 (9), p.1584-1591

2020

Volltextzugriff (PDF)

Regional brain atrophy in children with multiple sclerosis

NeuroImage (Orlando, Fla.), 2011-09, Vol.58 (2), p.409-415

2011

Volltextzugriff (PDF)

Hidradenitis and smoking

British journal of dermatology (1951), 2018-03, Vol.178 (3), p.810-811

2018

Volltextzugriff (PDF)

Standardized MR imaging protocol for multiple sclerosis : Consortium of MS centers consensus guidelines

AJNR. American journal of neuroradiology, 2006-02, Vol.27 (2), p.455-461

2006

Volltextzugriff (PDF)

Ocrelizumab versus interferon beta-1a in replacing multiple sclerosis

The New England journal of medicine, 2017-01, Vol.376 (3), p.221

2017

Volltextzugriff (PDF)

Ocrelizumab versus placebi in primary progressive multiplesclerosis

The New England journal of medicine, 2017-01, Vol.376 (3), p.209

2017

Volltextzugriff (PDF)

Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study

Journal of the neurological sciences, 2017-10, Vol.381, p.246-246

2017

Volltextzugriff (PDF)

Relating neocortical pathology to disability progression in multiple sclerosis using MRI

NeuroImage (Orlando, Fla.), 2004-11, Vol.23 (3), p.1168-1175

2004

Volltextzugriff (PDF)

Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion

NeuroImage (Orlando, Fla.), 2007-07, Vol.36 (4), p.1152-1158

2007

Volltextzugriff (PDF)

P 1 Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis – analysis of the phase III, double-blind, double-dummy, interferon beta-1a- controlled OPERA I and OPERA II studies

Clinical neurophysiology, 2017-10, Vol.128 (10), p.e326-e326

2017

Volltextzugriff (PDF)

P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFN β -1a–controlled OPERA I and OPERA II studies

Clinical neurophysiology, 2017-10, Vol.128 (10), p.e326-e327

2017

Volltextzugriff (PDF)

1 – 25 von 205

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(178)
Mit Volltextzugriff
(175)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(126)
Life Sciences & Biomedicine
(99)
Female
(62)
Humans
(62)
Biological And Medical Sciences
(55)
Male
(52)
Medical Sciences
(46)
Animals
(43)
Toxicology
(35)
Adult
(26)
Neurology
(23)
Neurosciences & Neurology
(23)
Physical Sciences
(23)
Food Science & Technology
(18)
Middle Aged
(18)
Clinical Neurology
(17)
Technology
(17)
Magnetic Resonance Imaging
(16)
Radiology, Nuclear Medicine & Medical Imaging
(16)
Rats
(16)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Validation Study of Multicenter Diffusion Tensor Imaging: Reliability of Fractional Anisotropy and Diffusivity Values

Manual Segmentation of MS Cortical Lesions Using MRI: A Comparison of 3 MRI Reading Protocols

Diffusion tensor imaging and cognitive speed in children with multiple sclerosis

Daclizumab HYP reduces total disability burden of patients with multiple sclerosis: results from an exploratory area under the curve analysis

Regional variations in normal brain shown by quantitative magnetization transfer imaging

Entorhinal cortex atrophy in epilepsy patients exhibiting normal hippocampal volumes

Neuroradiological efficacy of oral BG-12 for relapsing–/INS;remitting multiple sclerosis (RRMS): Integrated analysis of the Phase 3 DEFINE and CONFIRM studies

Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): Analysis from the phase 3 CARE-MS I study

Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study)

Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

PND63 Effects of BG-12 on Quality of Life in Relapsing–Remitting Multiple Sclerosis: Findings From the Phase 3 Define Study

Comparison of Multiple Sclerosis Cortical Lesion Types Detected by Multicontrast 3T and 7T MRI

Differential Regional Brain Atrophy Following Prophylactic Cranial Irradiation in Small Cell Lung Cancer Patients

Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions

Regional brain atrophy in children with multiple sclerosis

Hidradenitis and smoking

Standardized MR imaging protocol for multiple sclerosis : Consortium of MS centers consensus guidelines

Ocrelizumab versus interferon beta-1a in replacing multiple sclerosis

Ocrelizumab versus placebi in primary progressive multiplesclerosis

Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study

Relating neocortical pathology to disability progression in multiple sclerosis using MRI

Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion

P 1 Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis – analysis of the phase III, double-blind, double-dummy, interferon beta-1a- controlled OPERA I and OPERA II studies

P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFN β -1a–controlled OPERA I and OPERA II studies

Suchergebnisse filtern